Quanaobio

Quanao Biopharma is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the discovery and development of therapeutic antibodies targeting G protein-coupled receptors (GPCRs) and ion channels. The company leverages its proprietary platform to overcome traditional challenges in generating functional antibodies against complex multi-pass transmembrane proteins. Its lead program, QA001, is an anti-CCR8 monoclonal antibody designed to selectively deplete regulatory T cells within the tumor microenvironment. Quanao's pipeline also includes bispecific antibodies and treatments for chronic pain and respiratory diseases. The firm is backed by prominent venture capital investors and aims to address significant unmet needs in oncology and immunology.